P
ProteoMediX
Identification of novel biomarkers for the early detection of cancer
About ProteoMediX
Proteomedix is a healthcare company specializing in advanced diagnostic solutions for prostate cancer. Its flagship product, Proclarix, is a next-generation blood test designed to provide immediate clarity for patients with elevated PSA levels. Proclarix offers a non-invasive, precise, and fast diagnosis, reducing the need for painful and costly tissue biopsies. The test can be performed using the same blood sample as PSA testing, making it accessible and convenient for both patients and physicians. By improving patient management and satisfaction, Proclarix delivers strong health economic benefits to the healthcare system. Proteomedix primarily serves patients, physicians, and healthcare providers, operating in the medical diagnostics market. The company's business model focuses on selling its diagnostic tests to healthcare institutions and laboratories, generating revenue through test sales and partnerships.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Schlieren, Switzerland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Venture Kick
Series A3 investors entered at this stage
ZKB - Zürcher Kantonalbank
Altos Ventures
New Horizon Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ProteoMediX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ProteoMediX on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.